Caplin Point Laboratories (CAPLIPOINT) Share Price Fall Streak Extends for Second Straight Session
- September 30, 2026
- Posted by: Kunal Singla
- Category: News
Caplin Point Laboratories Share Price Fall Streak has extended for the second straight session, with the stock now lower by 6.18% from the streak start base price of Rs 2,852.7 to Rs 2,676.5. According to Univest data, the price pattern is confirmed, but no company-specific catalyst is established. The latest move keeps Caplin Point Laboratories Share Price Fall Streak in focus because the decline is happening across consecutive sessions rather than as a one-off slip.
The company’s market capitalisation stands at Rs 21,683.86 crore, which places this Caplin Point Laboratories Share Price Fall Streak within the Large Cap bucket reported for the stock. For readers, a second straight lower session matters because it shifts attention from a single-day move to a short run of weaker pricing. In this Caplin Point Laboratories Share Price Fall Streak, the important question is not just where the share price traded today, but how the streak changes the valuation read and how it compares with Healthcare peers now.
Caplin Point Laboratories (CAPLIPOINT) Share Price Fall Streak: Consecutive Decline Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,676.5 |
| Previous Close | Rs 2,743.4 |
| Today's Move | -Rs 66.90 (-2.44%) |
| Open | Rs 2,779.3 |
| High | Rs 2,794 |
| Low | Rs 2,676.5 |
| Market Capitalisation | Rs 21,683.86 crore |
Caplin Point Laboratories Share Price Today showed a clear lower session. The stock last traded at Rs 2,676.5, down Rs 66.9 or 2.44% from the previous close of Rs 2,743.4. It opened at Rs 2,779.3, touched a high of Rs 2,794 and a low of Rs 2,676.5, which was also the session’s low. That means the Caplin Point Laboratories Share Price Fall Streak ended the move at the bottom of the day’s range, a useful detail for readers tracking Caplin Point Laboratories Share Price Today.
The company’s market capitalisation was Rs 21,683.For Caplin Point Laboratories Share Price Today, the session began above the previous close, but the price moved lower through the day and finished at the low. That is the key price action point in this Caplin Point Laboratories Share Price Fall Streak: the second straight session is now visible in both the day’s change and the cumulative two-session move. The next read sits in the fundamentals.
What the Consecutive Declines Show
The Caplin Point Laboratories Share Price Fall Streak is more informative than a single-day decline because it shows two lower sessions in a row. The cumulative decline of 6.18% from Rs 2,852.7 to Rs 2,676.5 is the core streak figure, and it matters because the move is now built over consecutive sessions rather than one isolated market reaction. Univest data confirms the move itself, though no company-specific trigger has been identified.
For readers following Caplin Point Laboratories Share Price Fall Streak, the key interpretation is narrow and factual: the market price has moved down across both sessions, while the underlying business figures in this article have not changed over the same period. That makes the streak useful as a pricing lens, not as a statement about operations. This is also why Caplin Point Laboratories Share Price Fall Streak needs to be read alongside valuation, profitability and sector positioning rather than on price alone.
Caplin Point Laboratories (CAPLIPOINT) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 21,683.86 crore |
| P/E Ratio | 31.34x |
| P/B Ratio | 5.68x |
| ROE | 20.79% |
| ROCE | 24.97% |
| EPS | Rs 87.53 |
| Book Value Per Share | Rs 483.17 |
| Dividend Yield | 0.29% |
The important point is that Caplin Point Laboratories Share Price Fall Streak has not altered the reported earnings or book value numbers in this note; it has only changed the market price used to express the multiples. That makes the P/E and P/B a little easier to compare after the decline.For Caplin Point Laboratories Share Price Fall Streak, the fundamentals add context, not a verdict.
Caplin Point Laboratories has a market capitalisation of Rs 21,683.86 crore and falls in the Large Cap category, which gives readers a sense of company size before judging valuation. On valuation, P/E at 31.34x, P/B at 5.68x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 20.79% and ROCE of 24.97%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 87.53, book value per share of Rs 483.17, dividend yield of 0.29%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.43x, median ROE of 11.7%, median ROCE of 13.61%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 31.34x |
| Benchmark Median P/E | 32.43x |
| Benchmark Average P/E | 49.46x |
| Benchmark P/E Range | 3.4x to 699.02x |
| Company P/B Ratio | 5.68x |
| Benchmark Median P/B | 2.89x |
| Benchmark Average P/B | 4.38x |
| Company ROE | 20.79% |
| Benchmark Median ROE | 11.7% |
| Benchmark Average ROE | 10.68% |
| Company ROCE | 24.97% |
| Benchmark Median ROCE | 13.61% |
| Benchmark Average ROCE | 13.4% |
| Company Market Capitalisation | Rs 21,683.86 crore |
| Benchmark Median Market Cap | Rs 776.09 crore |
| Benchmark Average Market Cap | Rs 14,255.4 crore |
Caplin Point Laboratories operates in Healthcare within the Pharmaceuticals & Drugs industry, and the sector snapshot gives a strong comparative frame for the Caplin Point Laboratories Share Price Fall Streak. The company’s P/E of 31.34 is just below the industry median of 32.43, well below the industry average of 49.46, and inside the benchmark range of 3.4 to 699.02 across 199 companies. Its P/B of 5.68 is above the sector median of 2.89 and above the sector average of 4.38, which means Caplin Point Laboratories Share Price Fall Streak is still priced richer than the broader industry on book value terms.
On profitability, ROE at 20.79% stands above the sector median of 11.7% and sector average of 10.68%, while ROCE at 24.97% is also above the sector median of 13.61% and average of 13.4%. The benchmark scope is the same industry, and the market-cap median is Rs 776.09 crore versus a company market cap of Rs 21,683.86 crore. In that context, Caplin Point Laboratories Share Price Fall Streak shows a large company trading with stronger profitability ratios than the sector middle, even after the recent decline.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | SUNPHARMA | 4,41,477.63 | 36.9 | 5.16 | 14.85 | 19.11 |
| Divi's Laboratories | DIVISLAB | 2,53,031.38 | 85.99 | 14.24 | 16.19 | 21.51 |
| Torrent Pharmaceuticals | TORNTPHARM | 1,85,216.32 | 85.72 | 20.83 | 26.76 | 19.27 |
| Zydus Lifesciences | ZYDUSLIFE | 1,20,897.46 | 26.42 | 4.42 | 19.69 | 21.39 |
| Cipla | CIPLA | 1,12,205.15 | 33.15 | 3.18 | 11.83 | 16 |
Caplin Point Laboratories Share Price Fall Streak can also be read against listed peers in Pharmaceuticals & Drugs. On market cap, Caplin Point Laboratories at Rs 21,683.86 crore sits below Sun Pharmaceutical Industries at Rs 4,41,477.63 crore, Divi’s Laboratories at Rs 2,53,031.38 crore and Torrent Pharmaceuticals at Rs 1,85,216.32 crore, but above the other peers shown here. The size gap matters because the Caplin Point Laboratories Share Price Fall Streak is unfolding in a much smaller large-cap profile than the industry leaders.
On valuation, the company’s P/E of 31.34 is below Sun Pharmaceutical Industries and far below Divi’s Laboratories, Torrent Pharmaceuticals and Laurus Labs, while sitting above Zydus Lifesciences and Aurobindo Pharma Its ROE of 20.79% and ROCE of 24.97% are stronger than several peers shown, though Lupin posts higher figures on both measures. In peer terms, Caplin Point Laboratories Share Price Fall Streak has reduced price levels, but the operating return ratios remain competitive.
Why Investors Are Watching Caplin Point Laboratories
- The Caplin Point Laboratories Share Price Fall Streak has extended to a second straight session, which keeps the stock on the radar.
- The latest price moved to Rs 2,676.5, and the cumulative two-session decline is 6.18% from Rs 2,852.7.
- The company still shows ROE of 20.79% and ROCE of 24.97%, which helps frame the valuation after the decline.
- Its P/E of 31.34 is below the industry average and near the industry median, which adds context to Caplin Point Laboratories Share Price Fall Streak.
- Peers such as Sun Pharmaceutical Industries, Zydus Lifesciences and Lupin provide a useful comparison set for the stock’s current positioning.
About Caplin Point Laboratories
Caplin Point Laboratories is part of the Healthcare sector and the Pharmaceuticals & Drugs industry. For a reader following Caplin Point Laboratories Share Price Fall Streak, the business context that matters most is that the company is valued as a Large Cap and is tracked alongside other pharmaceutical names in the same industry benchmark. The latest Univest figures highlight a company with strong return ratios and a meaningful market cap, which is why the streak is being watched closely in a valuation context.
That keeps Caplin Point Laboratories Share Price Fall Streak anchored to verified market facts.
Track Caplin Point Laboratories Share Price on Univest
Use Caplin Point Laboratories (CAPLIPOINT) live share-price page, Univest top decliners screener, Univest market blogs to review live stock data, top decliners and related market analysis.
Track Caplin Point Laboratories Share Price on Univest to follow live price movement, key valuation ratios, market capitalisation, 52-week levels and market insights in one place. Caplin Point Laboratories Share Price Fall Streak is easiest to interpret when the price action, fundamentals and peer context are viewed together on a single stock page.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Reg. No. INH000013776, a subsidiary of Univest Communication Technologies Private Limited).
Frequently Asked Questions
Why is Caplin Point Laboratories Share Price falling today?
Ans. According to Univest data, the stock is in a second straight session of decline, with the latest move taking it to Rs 2,676.5. The confirmed price pattern is visible, but no company-specific catalyst is established.
What is Caplin Point Laboratories Share Price today?
Ans. Caplin Point Laboratories Share Price today stood at Rs 2,676.5, down 2.44% from the previous close of Rs 2,743.4. The session also marked the second straight lower close in the current streak.
How much has Caplin Point Laboratories Share Price fallen in the streak?
Ans. The stock has declined 6.18% across the streak, from the base price of Rs 2,852.7 to Rs 2,676.5. That cumulative move is the main feature of the current Caplin Point Laboratories Share Price Fall Streak.
What is Caplin Point Laboratories market capitalisation?
Ans. Caplin Point Laboratories has a market capitalisation of Rs 21,683.86 crore. The company is classified as Large Cap, which places the latest decline in the context of a sizeable listed pharmaceutical business.
Is Caplin Point Laboratories expensive compared with peers?
Ans. The company’s P/E ratio of 31.34 is below the industry average of 49.46 and near the industry median of 32.43. On P/B, it trades above the sector median, so the comparison is mixed.
What do ROE and ROCE show for Caplin Point Laboratories ?
Ans. ROE is 20.79% and ROCE is 24.97%, both above the healthcare sector median and average. Those figures show that Caplin Point Laboratories Share Price Fall Streak is not being driven by weak reported return ratios.
How does Caplin Point Laboratories compare with healthcare peers?
Ans. Caplin Point Laboratories has a smaller market cap than Sun Pharmaceutical Industries, Divi's Laboratories and Torrent Pharmaceuticals, but its ROE and ROCE remain competitive. That mix helps explain why the stock still draws attention after the.
What should investors watch next in Caplin Point Laboratories Share Price?
Ans. Investors may watch whether the second straight session of weakness extends or stabilises, along with how the stock’s P/E and P/B look relative to the sector. Univest data currently shows the price event, valuation context and peer position.
